Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013

Abstract

Supplemental Digital Content is available in the text

Risk of hospitalization for hypoglycemia among older Korean people with diabetes mellitus

“…In 2013, 1 person out of every 5 Korean people aged >65 years had diabetes mellitus. [2] As older diabetic patients have particular characteristics, a different approach to the management of diabetes is required compared with the approach used for young patients with diabetes, and the most serious problem is that older diabetic patients are very susceptible to hypoglycemia. [16] Longer diabetes durations, the presence of multiple comorbidities, and poor nutritional statuses could increase the risk of hypoglycemia among older patients.…”

“…We compared these to the results from another data in the same year, 2013. [2] Those data included people over the age of 30 with type 2 diabetes mellitus using the National Health Information Database and evaluated the treatment options for diabetes. The proportions of the patients who were treated with metformin (63.1% vs 80.4%) and DPP-4 inhibitors (25.9% vs 38.4%) were lower for the patients of all ages in our study population, but the use of sulfonylureas (47.6% vs 58.5%) and insulin (16.1% vs 16.4%) were comparable.…”

“…[1] Recent Korean epidemiologic data show that there has been a noticeable increase in the prevalence of diabetes mellitus, particularly among older people. [2] Since older patients with diabetes mellitus have particular characteristics, for example, the diabetes duration and the presence of comorbidities, the approach to the treatment of these patients should differ from the treatment approach used for younger patients with diabetes mellitus, [3] and the most serious problem is that older people with diabetes mellitus are very susceptible to hypoglycemia.…”

Risk factors of severe hypoglycemia requiring medical assistance and neurological sequelae in patients with diabetes

“…[26] Although it is expected that hypoglycemic episodes are less likely to occur with the use of newly developed antidiabetic medications, such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors, hypoglycemia remains a serious problem facing patients receiving diabetes treatment. Even if the American Diabetes Association recommendation of an HbA1c level less than 7% is applied, [31,32] only approximately half of diabetic patients is under adequate glycemic control, while the other half requires additional interventions, including additional hypoglycemic agents, to reach target glucose levels. However, as diabetes progresses, antidiabetic medications that increase the risk of hypoglycemia will be needed, and therefore, many patients with diabetes will still have taken sulfonylurea or received insulin treatment.…”

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

“…This is at least partly owing to the increasing number of T2DM patients in East Asian countries, which now comprise one-quarter of the global diabetes population [2]. Insulin is widely used to treat T2DM, and in Japan and Korea, approximately 15% of patients with T2DM are prescribed insulin (either alone or in combination therapy) [3,4]. Insulin can prevent glucose toxicity through its strong blood glucose-lowering effect, and early introduction of insulin therapy has been reported to prevent the progression of diabetes mellitus [5][6][7][8][9].…”